Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study

Engert, Andreas; Diehl, Volker; Franklin, Jeremy; Lohri, Andreas; Dörken, Bernd; Ludwig, Wolf‐Dieter; Koch, P.; Hänel, Mathias; Pfreundschuh, Michael; Wilhelm, Martin; Trümper, Lorenz; Aulitzky, Walter-Erich; Bentz, Martin; Rummel, Mathias; Sezer, Orhan; Müller–Hermelink, Hans–Konrad; Hasenclever, Dirk; Löffler, Markus

doi:10.1200/jco.2008.19.8820

Public

Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study

Published in Journal of Clinical Oncology • Aug 24, 2009

Authors:

Andreas Engert

Volker Diehl

Jeremy Franklin

Abstract

PURPOSE: The HD9 trial of the German Hodgkin Study Group compared two different doses (baseline and escalated) of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) chemotherapy regimen in 1,196 patients with advanced-stage Hodgkin's lymphoma...

Subject

Medicine

Procarbazine

ABVD

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!